Cancer Immunotherapy: Comprehensive Mechanism Analysis of Mesoporous-Silica-Nanoparticle-Induced Cancer Immunotherapy (Adv. Healthcare Mater. 10/2016)

Xiupeng Wang; Xia Li; Kazuko Yoshiyuki; Yohei Watanabe; Yu Sogo; Tadao Ohno; Noriko M Tsuji; Atsuo Ito

doi:10.1002/adhm.201670051

Cancer Immunotherapy: Comprehensive Mechanism Analysis of Mesoporous-Silica-Nanoparticle-Induced Cancer Immunotherapy (Adv. Healthcare Mater. 10/2016)

Adv Healthc Mater. 2016 May;5(10):1246. doi: 10.1002/adhm.201670051.

Authors

Xiupeng Wang¹, Xia Li¹, Kazuko Yoshiyuki¹, Yohei Watanabe², Yu Sogo¹, Tadao Ohno³, Noriko M Tsuji², Atsuo Ito¹

Affiliations

¹ Health Research Institute, Department of Life Science and Biotechnology, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8566, Japan.
² Biomedical Research Institute, Department of Life Science and Biotechnology, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8566, Japan.
³ School of Life Dentistry at Tokyo, The Nippon Dental University, Fujimi, Chiyoda-ku Tokyo, 102-0071, Japan.

PMID: 27226038
DOI: 10.1002/adhm.201670051

Abstract

A plain mesoporous silica (MS) nanoparticle without any immunomodulatory molecules enhances anti-cancer immunity in vivo. On page 1169, X.P. Wang, N. M. Tsuji, A. Ito and co-workers show that a plain MS nanoparticle promotes both Th1 and Th2 immune responses, and enhances the effector memory of CD4(+) and CD8(+) T cell populations in the three most important immune organs (bone marrow, lymph node and spleen) of mice.

Keywords: Th1 immunity; cancer immunoadjuvant; immune memory; mechanism; mesoporous silica nanoparticle.